Synova Healthcare Group Rated Buy/4 by Investrend Research Analyst Michael R. Anderegg, CFA.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- (Investrend Research Syndicate) Synova Healthcare Group (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). : SNVH) has been rated "Buy/4" in an initiating Benchmark Research report by Investrend Research analyst Michael R. Anderegg, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. , saying that "although Synova is early on its growth trajectory, we believe the company has attractive growth opportunities and could be a strong player in the menopause market going forward." Anderegg said the company recently announced that retail distribution for Menocheck(R) would expand to now include Rite Aid Rite Aid (NYSE: RAD) is a United States retailer and pharmacy chain, operating over 5,000 stores in 31 states and the District of Columbia. Rite Aid Corporation is one of the nation's leading drugstore chains. (NYSE NYSE See: New York Stock Exchange : RAD) stores. Other distributions include Albertson's (NYSE: ABS) and Cardinal Health (NYSE: CAH CAH congenital adrenal hyperplasia. CAH Congenital adrenal hyperplasia, see there ). The analyst added: Synova is an emerging company early in the process of rolling out distribution of innovative home and point of care diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease products that address important under-served or unmet medical needs while providing cost and ease of use advantages over current testing methods. Although the near term investment merits of the stock may be determined almost exclusively by the traction and performance of the two initial brands; Menocheck(R) and MenocheckPro(TM), we believe that the potential of additional future products exists and that the company could create additional intellectual property value going forward. The company has announced a distribution agreement to develop a non-invasive medical device targeting the fetal monitoring fetal monitoring Obstetrics A general term which can refer to any maneuver used to evaluate the fetus' status during pregnancy–eg, measurement of heartbeat and visual examination of the amniotic sac; however, as used, FM usually refers to the use of market. In addition, management is evaluating additional diagnostic product opportunities, including products that may prove useful in the areas of infertility, obstetrics and the detection of certain cancers. As is often the case with emerging growth companies, financial flexibility and funding adequacy are issues for investors to consider. Revenue has been modest and will be a primary metric to monitor for investors going forward. Synova recently raised $3,500,000 with the sale of 70 units consisting of 50,000 shares and warrants to purchase 40,000 shares, exercisable at $2 over a five year term. The full report, including important disclosures and disclaimers, is at http://www.investrendresearch.com and at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company. The analyst's credentials are at http://www.investrend.com/articles/secondlevel.asp?level=238 Synova Healthcare is enrolled in Investrend Research's pioneering professional research program, which facilitates independent analysts to provide coverage for shareholders in companies that otherwise would have little or no analyst following. Enrollment fees for Benchmark coverage are $24,800 and the fees are being paid by the company. Analysts are paid in advance of initial reports by Investrend Research to eliminate pecuniary Monetary; relating to money; financial; consisting of money or that which can be valued in money. pecuniary adj. relating to money, as in "pecuniary loss. interest, and neither the analyst nor principals of Investrend Research may own or trade in the stocks of companies under coverage. Synova Healthcare has been enrolled for shareholder-monitoring by the Shareholders Research Alliance (http://www.shareholdersresearch.com). Anyone interested in receiving alerts regarding Synova Healthcare should e-mail contact@investrend.com with "SNVH" in the subject line, or click on http://www.investrend.com/contact.asp. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion